Скачать или смотреть Boehringer Ingelheim’s Schizophrenia App: FDA Submission & Clinical Trial Results Explained

Boehringer Ingelheim is set to submit its groundbreaking schizophrenia treatment app, CT-155, to the FDA for clearance. Developed in collaboration with Click Therapeutics, this 16-week digital therapeutic targets under-addressed negative symptoms of schizophrenia, such as lack of motivation and anhedonia. In a 464-participant randomized control trial, the app demonstrated significant improvements compared to a control group, meeting its primary endpoint. Learn how this innovative app adapts face-to-face psychosocial treatments and complements antipsychotic medication. Stay updated on the future of digital therapeutics in mental health care. Keywords: schizophrenia treatment, digital therapeutics, FDA submission, Boehringer Ingelheim, CT-155, mental health apps, clinical trial results.